Abiopharma

Ceased to serve as external director – Yifat Adoram Zak as of 4.8.26

Companys Presentation

Q2/half-year report for 2026

The company’s liabilities position as of 30.6.26, by maturity dates

Started to be an interested party - Migdal Insurance and Financial Holdings Ltd.

Earnings Presentation - Q2 2026

Report of Periodic or Interim Report

Second Quarter 2026 Financial Results

Communiqué de presse : MenQuadfi de Sanofi approuvé dans l’UE pour une utilisation chez les nourrissons dès l’âge de six semaines contre les infections invasives à méningocoques

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

Wix Reports Second Quarter 2026 Results

Events and transactions

General Announcement: Net Asset Value ("NAV") as of 03 August 2026

Procore Technologies, Inc. Announces Pricing of Upsized $825.0 Million Offering of Convertible Senior Notes